Abstract
Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme, statins, are powerful cholesterol-lowering medications and have provided outstanding contributions to the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) is one of the major modifiable cardiovascular risk factors, indeed, every 1.0 mmol/L (38.7 mg/dL) reduction in LDL cholesterolaemia corresponds to a 21% lowering in the risk of major vascular events. In this context, the pharmacological approach with PCSK9 monoclonal antibodies is considered a promising non-statin therapeutic option for the management of lipid disorders in patients with persistent cardiovascular risk, including patients with diabetes mellitus. Data from two large clinical trials have indisputably demonstrated the efficacy of alirocumab and evolocumab in preventive major adverse cardiovascular events in high risk, secondary-prevention patients with clinical manifestation of atherosclerotic cardiovascular diseases. Finally, PCSK9 monoclonal antibodies did not increase the risk of serious adverse events, neurocognitive events, new-onset of diabetes, muscle-related events, or myalgia.
References
Oct 11, 2005·Lancet·C BaigentUNKNOWN Cholesterol Treatment Trialists' (CTT) Collaborators
Nov 12, 2010·Lancet·UNKNOWN Cholesterol Treatment Trialists’ (CTT) CollaborationR Collins
May 20, 2011·Nature·Peter LibbyGöran K Hansson
Oct 23, 2012·Journal of the American College of Cardiology·Brian A FerenceJohn M Flack
Aug 2, 2014·Journal of the American College of Cardiology·S Matthijs BoekholdtJohn J P Kastelein
Dec 10, 2014·Antioxidants & Redox Signaling·Zufeng DingJawahar L Mehta
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Mar 26, 2016·Atherosclerosis·Jin M ChengK Martijn Akkerhuis
Aug 2, 2016·Atherosclerosis·Nicola FerriAlberto Corsini
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
May 5, 2017·Journal of the American Heart Association·Massimiliano RuscicaUNKNOWN Brisighella Heart Study Group
May 30, 2017·Expert Opinion on Biological Therapy·Nicola FerriMassimiliano Ruscica
Sep 2, 2017·Lancet·Robert P GiuglianoUNKNOWN FOURIER Investigators
Sep 21, 2017·The Lancet. Diabetes & Endocrinology·Marc S SabatineTerje R Pedersen
Feb 6, 2018·Scientific Reports·Chiara RicciNicola Ferri
Feb 24, 2018·Journal of the American College of Cardiology·Marina CameraNicola Ferri
Apr 8, 2018·Circulation·Marc S SabatineTerje R Pedersen
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Dec 14, 2018·Circulation·Eeva SlizPeter Würtz
Dec 12, 2018·Circulation·Eeva SlizPeter Würtz
Dec 12, 2018·The Canadian Journal of Cardiology·Ricky D TurgeonGlen J Pearson
Dec 14, 2018·Journal of the American College of Cardiology·Paolo PoggioMarina Camera